COMPASS Pathways Achieves Primary Endpoint in Second Phase 3 TRD Trial, Plans Q4 NDA Submission

summarizeSummary

COMPASS Pathways announced successful Phase 3 trial results for COMP360 in treatment-resistant depression, meeting the primary endpoint with strong efficacy and safety data, and plans for a Q4 NDA submission.

check_boxKey Events

• Phase 3 COMP006 Trial Success

  The COMP006 trial, the second of two pivotal Phase 3 trials for COMP360 in treatment-resistant depression (TRD), successfully achieved its primary endpoint, demonstrating a highly statistically significant reduction in symptom severity (p<0.001).

• Clinically Meaningful Efficacy

  COMP360 25 mg showed a clinically meaningful difference of -3.8 points in MADRS scores compared to the 1 mg group at Week 6, with rapid onset of action observed from the day following administration.

• Favorable Safety Profile

  Across both COMP005 and COMP006 trials, COMP360 demonstrated a generally well-tolerated and safe profile, with most treatment-emergent adverse events (TEAEs) being mild or moderate and resolving within 24 hours.

• Path to Regulatory Submission

  The company has requested a meeting with the U.S. FDA to discuss a rolling submission and review, with an expectation to complete a New Drug Application (NDA) submission in Q4, leveraging its Breakthrough Therapy designation.

auto_awesomeAnalysis

COMPASS Pathways plc announced highly positive results from its second pivotal Phase 3 trial (COMP006) for COMP360 in treatment-resistant depression (TRD). The trial met its primary endpoint with statistically significant and clinically meaningful reductions in depression severity, demonstrating rapid onset and durable effects. This follows previously disclosed positive results from the COMP005 trial. The consistent efficacy and generally well-tolerated safety profile across both trials significantly de-risk the program. The company's plan to request a meeting with the FDA for a rolling submission and review, with an anticipated NDA submission in Q4, indicates an accelerated path to market, leveraging its Breakthrough Therapy designation. This is a critical milestone for the company, positioning COMP360 as a potentially highly differentiated treatment for a patient population with significant unmet needs.